The risk of colorectal cancer in patients with type 2 Diabetes: Associations with treatment stage and obesity

Diabetes Care

Volumn 38, Issue 3, 2015, Pages 495-502

  Peeters, Paul J H L ^a   Bazelier, Marloes T ^a   Leufkens, Hubert G M ^a   De Vries, Frank ^a,b,c   De Bruin, Marie L ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; ADOLESCENT; COLORECTAL NEOPLASMS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; INCIDENCE; MIDDLE AGED; PATHOLOGY; RISK FACTOR; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84941127629     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1175     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst 2005;97: 1679-1687.
3. Danaei G, Finucane MM, Lu Y, et al.; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2z7 million participants. Lancet 2011;378:31-40.
4. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:1147-1154.
5. Stocks T, Lukanova A, Bjørge T, et al.; Metabolic Syndrome Cancer Project Me-Can Group. Metabolic factors and the risk of colorectal cancer in 580, 000 men and women in the metabolic syndrome and cancer project (Me- Can). Cancer 2011;117:2398-2407.
6. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: A meta-analysis of prospective studies. Am J Clin Nutr 2007;86:556- 565.
7. Golay A, Chen YD, Reaven GM. Effect of differences in glucose tolerance on insulin's ability to regulate carbohydrate and free fatty acid metabolism in obese individuals. J Clin Endocrinol Metab 1986;62:1081-1088.
8. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. Lancet 2009;373: 2215-2221.
9. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22- 29.
10. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
11. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996;45:633-638.
12. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 2012;12:159-169.
13. Koenuma M, Yamori T, Tsuruo T. Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res 1989;80:51-58.
14. Bjork J, Nilsson J, Hultcrantz R, Johansson C. Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29. Scand J Gastroenterol 1993;28:879- 884.
15. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996;5:1013-1015.
16. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-625.
17. Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:546-553.
18. Parkinson J, Davis S, vanStaa TP. The general practice research (GPRD) database: Now and the future [online text]. In Pharmacovigilance. 2nd ed. Mann RD, Andrews EB, Eds. Hoboken, NJ, John Wiley & Sons, 2007, p. 341-348.
19. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: A systematic review. Br J Gen Pract 2010;60:e128-e136.
20. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: A systematic review. Br J Clin Pharmacol 2010;69:4-14.
21. Bazelier MT, Gallagher AM, van Staa TP, et al. Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? Pharmacoepidemiol Drug Saf 2012;21:507-514.
22. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-1596.
23. Tiengo A, Del Prato S. The combined treatment with insulin and sulfonylurea in non-insulindependent diabetic patients with secondary failure. Rationale and guidelines. Diabetes Res Clin Pract 1988;4(Suppl. 1):75-81.
24. Lloret-Linares C, Greenfield JR, Czernichow S. Effect of weight-reducing agents on glycaemic parameters and progression to type 2 diabetes: A review. Diabet Med 2008;25: 1142-1150.
25. Erdem G, Dogru T, Tasci I, et al. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 82:214-218.
26. Houmard JA, Tanner CJ, Slentz CA, Duscha BD, McCartney JS, Kraus WE. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol (1985) 2004;96: 101-106.
27. Johnson CM, Wei C, Ensor JE, et al. Metaanalyses of colorectal cancer risk factors. Cancer Causes Control 2013;24:1207-1222.
28. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989;79:340-349.
29. Starup-Linde J, Karlstad O, Eriksen SA, et al. CARING (CAncer Risk and INsulin analoGues): The association of diabetes mellitus and cancer risk with focus on possible determinants - A systematic review and a meta-analysis. Curr Drug Saf 2013;8:296-332.
30. Karam JH, Grodsky GM, Forsham PH. Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 1963;12:197-204.
31. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet 2014;383:1068-1083.
32. Kahn SE, Prigeon RL, Schwartz RS, et al. Obesity, body fat distribution, insulin sensitivity and islet beta-cell function as explanations for metabolic diversity. J Nutr 2001;131:354S-360S.
33. Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2013;22: 2258-2268.
34. Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer. Biochim Biophys Acta 2013;1831:1499-1508.
35. Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf 2013;22:168-175.